JP2023549837A5 - - Google Patents
Info
- Publication number
- JP2023549837A5 JP2023549837A5 JP2023528580A JP2023528580A JP2023549837A5 JP 2023549837 A5 JP2023549837 A5 JP 2023549837A5 JP 2023528580 A JP2023528580 A JP 2023528580A JP 2023528580 A JP2023528580 A JP 2023528580A JP 2023549837 A5 JP2023549837 A5 JP 2023549837A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- pharmaceutical composition
- hyaluronidase
- composition according
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115002P | 2020-11-17 | 2020-11-17 | |
| US63/115,002 | 2020-11-17 | ||
| PCT/EP2021/082031 WO2022106487A1 (en) | 2020-11-17 | 2021-11-17 | Treatment or prevention of a disease or disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549837A JP2023549837A (ja) | 2023-11-29 |
| JP2023549837A5 true JP2023549837A5 (enExample) | 2024-11-25 |
Family
ID=78806517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528580A Pending JP2023549837A (ja) | 2020-11-17 | 2021-11-17 | 疾患又は障害の治療又は予防 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230405094A1 (enExample) |
| EP (1) | EP4247333A1 (enExample) |
| JP (1) | JP2023549837A (enExample) |
| KR (1) | KR20230110763A (enExample) |
| CN (1) | CN116437901A (enExample) |
| AU (1) | AU2021382120A1 (enExample) |
| CA (1) | CA3196877A1 (enExample) |
| IL (1) | IL302860A (enExample) |
| MX (1) | MX2023005760A (enExample) |
| WO (1) | WO2022106487A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024177927A1 (en) * | 2023-02-20 | 2024-08-29 | Lindy Biosciences, Inc. | Hyaluronidase particles, compositions comprising the same and methods of making and using the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| CN101478950B (zh) * | 2006-06-23 | 2013-02-06 | 泰博特克药品有限公司 | Tmc278的水性悬浮液 |
| SI4269578T1 (sl) * | 2008-03-06 | 2024-07-31 | Halozyme, Inc. | Sestava topne hialuronidaze |
| TWI489994B (zh) * | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| US20090311237A1 (en) * | 2008-04-14 | 2009-12-17 | Frost Gregory I | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
| HUE028832T2 (en) * | 2009-09-17 | 2017-01-30 | Baxalta Inc | Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation |
| HRP20201241T1 (hr) * | 2011-04-15 | 2020-11-27 | Janssen Pharmaceutica N.V. | Nanosuspenzije lijeka osušene zamrzavanjem |
| MA46761A (fr) * | 2016-11-10 | 2019-09-18 | Translate Bio Inc | Administration sous-cutanée d'arn messager |
-
2021
- 2021-11-17 CA CA3196877A patent/CA3196877A1/en active Pending
- 2021-11-17 CN CN202180076908.9A patent/CN116437901A/zh active Pending
- 2021-11-17 US US18/037,218 patent/US20230405094A1/en active Pending
- 2021-11-17 JP JP2023528580A patent/JP2023549837A/ja active Pending
- 2021-11-17 MX MX2023005760A patent/MX2023005760A/es unknown
- 2021-11-17 AU AU2021382120A patent/AU2021382120A1/en not_active Abandoned
- 2021-11-17 WO PCT/EP2021/082031 patent/WO2022106487A1/en not_active Ceased
- 2021-11-17 IL IL302860A patent/IL302860A/en unknown
- 2021-11-17 KR KR1020237020276A patent/KR20230110763A/ko not_active Withdrawn
- 2021-11-17 EP EP21815467.2A patent/EP4247333A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11248000B2 (en) | Quinazoline and indole compounds to treat medical disorders | |
| ES3040193T3 (en) | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | |
| US20170057983A1 (en) | Phosphonate Compounds for Treatment of Medical Disorders | |
| US11517628B2 (en) | Particles for spatiotemporal release of agents | |
| US10385097B2 (en) | Ether compounds for treatment of medical disorders | |
| ES2555279T3 (es) | Neuroprotección en enfermedades desmielinizantes | |
| US20250092083A1 (en) | Sterol based ionizable lipids and lipid nanoparticles comprising the same | |
| CN108026533B (zh) | 拮抗性pdl1适体及其在癌症治疗中的应用 | |
| ES2712688T3 (es) | Métodos y composiciones para el tratamiento de la esclerosis múltiple y trastornos asociados | |
| TW201720438A (zh) | 用於治療醫學病症之化合物 | |
| JP2013507131A5 (enExample) | ||
| CN105188710A (zh) | 包含缓冲的氨基烷基氨基葡糖苷磷酸酯衍生物的组合物及其用于增强免疫应答的用途 | |
| JP2023549837A5 (enExample) | ||
| JP7066669B2 (ja) | 炎症性関節疾患の治療方法 | |
| Bahmanpour et al. | Nanotechnology for pulmonary and nasal drug delivery | |
| Ye et al. | Macrophages as nanocarriers for drug delivery: novel therapeutics for central nervous system diseases | |
| Jallow et al. | Versatility of LNPs across different administration routes for targeted RNA delivery | |
| Cai et al. | Nanomaterials in controlled drug release | |
| JPWO2004035779A1 (ja) | ウイルスエンベロープを用いた生体分子の導入方法ならびにそのための組成物およびシステム | |
| Chen et al. | A comprehensive analysis of biopharmaceutical products listed in the FDA’s Purple Book | |
| JP6820841B2 (ja) | ペグ化インターフェロンのための投薬計画 | |
| Komalla et al. | Biologics and vaccines for nasal and pulmonary drug delivery | |
| JP2023546923A5 (enExample) | ||
| JP2023550079A5 (enExample) | ||
| Qiu et al. | Pulmonary delivery of Messenger RNA (mRNA) therapeutics for respiratory diseases |